Neuren Pharmaceuticals Ltd
ASX:NEU
Neuren Pharmaceuticals Ltd
Cash & Cash Equivalents
Neuren Pharmaceuticals Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash & Cash Equivalents
AU$3.2m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-17%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash & Cash Equivalents
AU$110.1m
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Cash & Cash Equivalents
AU$48.4m
|
CAGR 3-Years
42%
|
CAGR 5-Years
12%
|
CAGR 10-Years
41%
|
|
|
Probiotec Ltd
ASX:PBP
|
Cash & Cash Equivalents
AU$12.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
34%
|
|
|
Argenica Therapeutics Ltd
ASX:AGN
|
Cash & Cash Equivalents
AU$15.9m
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Cash & Cash Equivalents
AU$28.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
12%
|
|
Neuren Pharmaceuticals Ltd
Glance View
Founded in 1993, Neuren Pharmaceuticals Ltd has carved a niche for itself within the biotech industry, focusing primarily on neurological and neurodevelopmental disorders. The company operates at the intriguing intersection of innovation and medicine, where the stakes are high, but so are the potential rewards. Neuren has its headquarters in Australia and has oriented its research towards developing therapies that could change the lives of those affected by conditions like Rett syndrome and Fragile X syndrome. By adopting a strategic approach that combines cutting-edge science with a relentless focus on unmet needs, Neuren positions itself uniquely through its proprietary compounds such as trofinetide and NNZ-2591, which are at the core of its research endeavors. The company's business model hinges on a dual approach: developing its own drugs while simultaneously fostering partnerships with larger pharmaceutical companies to bring these therapies to market. This model allows Neuren to share the substantial costs and risks inherent in drug development while benefiting from the expanse of its partners' distribution networks and market insights. Revenue generation kicks in primarily through milestone payments, royalties, and licensing agreements as these partners help navigate the rigorous phases of clinical trials and regulatory approvals. Financial stability is thus intricately tied to clinical successes and strategic alliances, allowing Neuren to balance the speculative nature of biotech investments with the promise of transformative medical breakthroughs.
See Also
What is Neuren Pharmaceuticals Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
3.2m
AUD
Based on the financial report for Dec 31, 2024, Neuren Pharmaceuticals Ltd's Cash & Cash Equivalents amounts to 3.2m AUD.
What is Neuren Pharmaceuticals Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-17%
Over the last year, the Cash & Cash Equivalents growth was -82%. The average annual Cash & Cash Equivalents growth rates for Neuren Pharmaceuticals Ltd have been -56% over the past three years , -26% over the past five years , and -17% over the past ten years .
You don't have any saved screeners yet